 kstew call note lot run usual
 js call finish littl bit ago apolog delay took bit clean note
im bloomberg im chat ith follow -up qs
here quick rundow highlight thought read-through
realli good clean quarter erent major one-tim adjust ere discuss call chang
view quarter realli good quarter view stock deserv trade higher today
updat litig includ addit accrual
 earli commentari around framework manag typic provid guidanc year ahead
report result provid color today call effort provid visibl outlook manag
comment expect pharma deliv above-market perform view around expect medic devic
continu sale momentum expect consum continu focu optim portfolio improv profit
incom big focu given gain year expect record approxim half hat ill also
expect tax rate
medic devic coupl adjust trend still favor right directionacceler
adjust acquisitions/divestitures/fx medic devic sale ere manag estim benefit
due buy ahead consumpt tax chang japan primarili impact vision busi grow th rate ex-thi
 hich strongest grow th year manag note sell day impact minim ere
put take surgiflo month rebat adjust trauma vet channel purchas ith busi
alw ay put take seem red start get groov back slow ly far overal market
trend seem like util environ least stabl good sign rest med-tech report season
digit surgeri robot continu view digit surgeri big opportun assess program j/verb
hire kurt azarbarzin ceo ho ith ho came surgiquest acquisit note
chang timelin formal ill provid updat assess complet expect occur end
year updat manag note done end-to-end procedur platform said seem like
us delay longer time market seem like expect launch hugo surgic robot fall
view j/verb beyond
orthoped ere reluct make ortho read-thru quarter call js result say look like
continu lose us share knee said much js us knee busi dow albeit better
look ahead manag continu believ competit posit improv ith attun revis
cementless offici launch orthotaxi knee robot system ont approv estim
compani plan fda submiss timelin unchang
great rest day reach ith question chat bloomberg email rate share equal eight
wolk evp cfo
pleas ith result exceed outlook provid start year
strong revenu earn grow th hile make invest advanc innov
busi us ork litigi environ result show busi fundament strong
pharma deliv above-market perform across broad base therapeut area led double-digit grow th key product
even face biosimilar gener pleas ith progress quarter regulatori approv submiss notabl
fda approv erleada treatment metastat castrat sensit prostat cancer base titan trial stelara
ulcer coliti eu addit indic product
consum health third quarter show ed continu strength area priorit earlier year like beauti
over-the-counter busi ere fuel new product recent acquisit larg market consum grow competit ith
market hile also improv profit
medic devic busi continu acceler grow th ere tailw ind hich ill discuss
best quarterli grow th sinc intervent solut anoth quarter double-digit grow th surgeri improv
orthoped progress continu success execut multipl launch quarter compani ell posit
continu momentum
 sale total billion increas y/i report
oper sale ex-transl fx neg impact
us ere ou sale ere report basi oper ou sale ere exclud fx impact
exclud acquisit divestitur ell fx sale ere us ou
exclud special charg adjust net incom ere billion y/i adjust ep y/i
consum sale total oper basi
exclud acquisit divestitur sale ere ith strong us due strong beauti over-the-counter ou
ytd double-digit grow th across region e-commerc
beauti franchis grew adjust dr ci labo roc neutrogena aveeno deliv strong perform due
share grow th combin ith time promot club channel us share grow th neutrogena realiz
facial moistur treatment cleans sun protect categori avenno gain ere due hair product line relaunch
over-the-counter sale grew global ex zarbe acquisit us over-the-counter adjust grow ing share adult
babi declin global hen adjust exclud impact babi center divestitur share declin
 primarili due relaunch restock johnson babi relaunch mostli us ex-that estim babi
 ould flat quarter
pharma sale ere double-digit grow th key product
us sale ere ou
gener zytiga impact us respect
immunolog driven strong doubl digit perform stelara tremfya simponi simponi aria continu
eros remicad due increas discount share loss stelara grow th almost primarili crohn indic
tremfya sale ere almost file tremfya ith fda applic treatment adult ith activ psoriat arthriti
oncolog darzalex sale grew global adjust impact reimburs ou us grew strong market
grow th increas market share imbruvica grew global market share gain market grow th zytiga
sale declin us due gener competit grow th ou
neurosci paliperidon long-act perform ell grow ing progress ith launch spravato ith
site certifi rem program activ treat patient
cardiovascular metabol sale declin primarili driven declin invokama biosimilar competit
procrit xarelto flat volum increas off-set rebat increas legisl rate donut hole
along ith higher medicar donut hole util yesterday xarelto approv treatment vte medic ill
pulmonari hypertens portfolio grew strong opsumit uptravi off-set tracleer hich impact
recent gener entri us continu gener competit ou
exclud acquisit divestitur primarili lifescan diabet advanc steril product asp sale grow th
grow th aid one-tim grow th larg forw ard buy ahead consumpt tax chang japan
primarili impact vision busi manag expect major sell-through ith remaind occur
intervent solut grew led continu strength electrophysiolog busi ith grow th continu
double-digit grow th trend region driven ablat advanc cathet contribut atrial fibril procedur market
grow th quarter result af progress trial attest show ed cathet ablat less like develop persist af
cerenovu busi doubl digit grow th driven new product includ embotrap
vision sale grow th driven contact lens busi hich led daili dispos total vision grow th
aid forw ard buy japan hich ad global grow th surgic vision launch techni vision intraocular lens
orthoped grow th continu improv ith signific acceler quarter deliv grow th largest grow th sinc
manag comment progress reflect continu execut innov commerci strategi aim
hip grew driven leadership anterior approach continu strong demand acti primari stem
trauma grew global driven market grow th support adopt new er innov manag
also note one-tim rebat reserv adjust us orth almost global adjust item drive
grow th line ith global market
spine dow less ith us primari driver manag note continu see stabil
perform driven new product viper prime system mi new ly launch conduit interbodi
platform ith eit cellular titanium print technolog treat degen spine diseas
knee grow th ith declin us strong grow th ou manag comment ou
grow th market perform led new innov note attun revis plu us
manag note posit uptak attun revis note quarter launch attun revis
knee us select market around orld
price pressur impact modest improv neg spine hip trauma knee dow
surgeri advanc surgeri deliv global grow th led energi driven share gain new product asia pac
biosurgeri grew approxim grow th region particularli aspac surgiflo back market end juli
 month market quarter impact grow th ound closur grew almost driven
share gain convent barb sutur continu strong market grow th china time purchas vet channel
favor impact global grow th almost
expect sell day minor impact expect signific impact
adjust ep y/i
cog deliv driven fx
sg improv due mix plan priorit consum med devic plan leverag pharma
 higher higher invest medic devic relat robot digit program
incom driven conting liabil revers
net interest low er driven net invest hedg low er interest due low er debt
effect tax rate versu driven adjust tax reserv posit
wolk evp cfo commentari
expect experi higher level invest futur digit surgeri offer invest pharma cart-t darzalex
sub-q line extens immunolog other evalu strateg transact ell complet billion share
repurchas program author
courtesi
 manag note provid quarterli guidanc provid guidanc offer comment
elev incom million due lifescan divestitur manag note noth els
plan year look beyond still final plan
revenu ise manag comment expect pharma busi continu deliv market perform
expect medic devic continu sale momentum consum continu focu optim portfolio hile
manag comment ith respect ould continu balanc improv oper effici ith invest
incom expens manag note expect record approxim half hat guidanc
manag note prefer invest progress robust pipelin asset call digit surgeri
note bolster auri transact
manag note expect tax rate rang similar full-year tax rate
 hile manag forecast currenc note base currenc ould headw ind less year impact
outlook expect ep manag still formul plan next year manag comment feel
good momentum ith respect incom ratio sale grow th ratio ever note littl bit earli
comment js team ork plan note ambiti goal next year manag
comment investor stay tune probabl best direct could say time
billion repurchas complet one think repurchas go forward repurchas probabl least
prefer capit option ill continu evalu go forw ard ell option
vision care perform surgic manag note strong quarter medic devic overal
 forw ard consumpt one take grow th hich strongest grow th year
manag think medic devic busi turn corner contact lens healthi quarter strong grow th
unit state us busi challeng due competit inroad strengthen innov manag believ
seen soften lasix market
tremfya competit pharma realli strong quarter exclud zytiga grow th tremfya grew
file applic pa august manag pleas ith trajectori believ competit mechan believ
competit profil vs
liabil compani address overhang three headlin grabber risperd judgement think
egregi ill appeal amount opioid oklahoma brought public nuisanc settl tw counti
ohio talc plaintiff spent million advertis law suit go continu defend product say know
safe three case last eek continu focus bring better healthcar solut
impact talc consum busi consum busi focus deliv deliv solid grow th
prioriti area identifi begin year grow th beauti
color see china busi china continu perform ell overal grow th medic
devic around pharma consum impact ith tariff billion quarter
advanc surgeri busi turn around us manag comment ould challeng get
digit surgeri busi see strong perform outsid unit state
medic devic sequenti improv dont anticip linear improv think ill accomplish grow th benefit
commerci improv also innov agenda launch cementless knee ill symphoni launch
spine think ill effect ill lot innov month ep new cathet take procedur hour
hour digit surgeri robot ith file also digit surgic ith monarch verb
darzalex outlook manag note look expand across therapi importantli file subcutan
formul think ill import catalyst grow th base strength date addit data opportun
 ith front line sub-q think there still strong perform grow th go forw ard
robot digit surgeri manag comment couldnt bullish js opportun ith footprint
today open laparoscop technolog monarch great start chest end octob
 ill post-market data heathi pipelin ith ablat also consid potenti applic endo-urolog
kidney stone applic gi endoscopi brought new leader verb kurt azarbarzin encourag say auri
verb conduct end end procedur gener surgeri take best also fred moll engag ith
orthoped expect file orthoped program middl complet assess around iplatform
verb creat valu right chang timelin assess complet stay tune
monarch hile earli limit revenu date pleas ith placement number placement today
robot spine spine focus stabil spine key top market think date digit
surgeri limit usag spine
gener biosimilar headwind call number sit think see billion
littl less hat anticip number gener eros rate catch think get next year ill ork
done ith
xarelto line extens return growth excit new indic indic move forw ard
get past donut hole issu see grow th asset complet year
outlook feel good top-lin grow th ith medic devic expect around market see
market influenc higher-grow th segment market dont pronounc
presenc pharma market grow th consum expect competit ith market hich see focu skin
self-car improv profit pleas ith pipelin item ere advanc
increment growth hip knee pleas ith hip around strong portfolio lead ay ith anterior
complet acquisit joint point knee comment encourag ith perform fuel ou perform
attun perform ell ork legaci transit ith sigma full portfolio ith attun revis
launch attun cementless
verb provid detail timelin brought new ceo day ago kurt azarbarzin let get
hood still middl expect complet end year expect give
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target methodolog base enterpris valu sale appli multipl
sale estim billion arriv price target smid cap med-tech name ith similar grow th outlook current
trade
risk may imped achiev barclay research valuat price risk includ abil
integr transact particularli buffalo filter new product approv competit price pressur fda action abil
expand oper margin abil reduc debt
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog price target reflect sum-of-the-part analysi use pharma med tech consum peer
adjust rel grow th ep impli blend pe ep sinc share
trade averag pe market pe
risk may imped achiev barclay research valuat price nside risk greater pressur
biosimilars/gener increas pricing/reb advers litig rule pipelin failur competit product launch fda
action healthcar reform dilut deal integr issu upsid risk includ new product success success capit
deploy favor litig outcom competit product failur rotat defens stock
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog set price target primarili reli forw ard price-to-earnings methodolog price target
appli target pe calendar ep estim discount med-tech compani
trade hich believ appropri given slow er grow th profil sinc trade averag discount
 ever past year compani improv grow th profil durabl mid-singl
digit grow th hich believ arrant premium current trade calendar ep estim
thu expect pe multipl hold
risk may imped achiev barclay research valuat price nside risk includ fx rate
strengthen us dollar hich could pressur earn stock perform new product key futur success
compani thu extent compani unabl receiv fda approv could advers impact futur
outlook product includ compani surgic robot platform hich expect regulatori approv outsid unit
state begin key product includ micra av interstim micro minim futur iter continu blood
glucos monitor devic transcathet valv system upsid greater success ith new product margin expans
risk includ signific reimburs chang competit pressur product failur fda govern
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
unless otherw ise indic price sourc refinitiv reflect close price relev trade market hich may
last avail price time public
